Technology | Stents Bare Metal | December 09, 2015

Medinol Begins U.S. Commercialization of New Coronary Stent

NIRxcell CoCr Stent System first product launched from new U.S. headquarters

December 9, 2015 — Medinol U.S. recently opened their commercial business in Parsippany, New Jersey, followed by the launch of the NIRxcell CoCr Stent System.

During the recent 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco, Medinol Ltd. hosted a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", where a physician panel discussed the key attributes of the NIRxcell System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved). Physician faculty included David E. Kandzari, M.D., Piedmont Heart Institute; Jim Zidar, M.D., North Carolina Heart and Vascular; Rajiv Jauhar, M.D., North Shore University Medical Center; Peter Smits, M.D., Maasstad Ziekenhuis, Rotterdam, the Netherlands; and Shmuel Banai, M.D., The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasized the design of the BIONICS/NIREUS clinical trials that have recently completed enrollment. 

Kandzari commented, "The delivery system is unlike in any other product on the market" and Medinol's approach to trial design "was entirely unlike any other pivotal trial as it included a 'more comers' patient population."

On an annual basis, approximately 800,000 patients undergo coronary stenting procedures in the United States. Healthcare providers continue to look for novel, effective and efficient solutions to treat their patients.

For more information:

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init